Why the study?
Dysregulation of the Wnt/β-catenin signalling pathway is implicated in post-MI cardiac remodelling, but the cardioprotective potential of the β-catenin inhibitor sulindac in an isoproterenol-induced MI model remained to be evaluated.
Does sulindac attenuate isoproterenol-induced myocardial injury in a rat model?
Population
Wistar rats with isoproterenol-induced myocardial infarction
Comparison
Oral sulindac (2, 4, and 10 mg/kg) vs control
Design
In vivo animal study and molecular docking
Key result
Sulindac significantly attenuated isoproterenol-induced myocardial injury in rats, reducing cardiac biomarkers, oxidative stress, and β-catenin levels in a dose-dependent manner (p<0.05).
Authors
Loading...
No immediate clinical role in MI; hypothesis-generating for β-catenin inhibition in remodeling.
Does sulindac attenuate isoproterenol-induced myocardial injury in a rat model?
Sulindac demonstrates dose-dependent cardioprotective effects in a rat model of isoproterenol-induced myocardial infarction, potentially via Wnt/β-catenin pathway modulation.
Patil et al. (2026) studied Myocardial infarction (n=48). Sulindac vs. Isoproterenol only (negative control) was evaluated. Sulindac significantly attenuated isoproterenol-induced myocardial injury in rats, reducing cardiac biomarkers, oxidative stress, and β-catenin levels in a dose-dependent manner (p<0.05).